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A commentary on
Epigenetic Regulation of Phosphodiesterases 2A and 3AUnderlies Compromised β-Adrenergic
Signaling in an iPSCModel of Dilated Cardiomyopathy
by Wu, H., Lee, J., Vincent, L. G., Wang, Q., Gu, M., Lan, F., et al. (2015). Cell Stem Cell 17. 89–100.
doi: 10.1016/j.stem.2015.04.020
Wu et al. (2015) describe pioneering work that utilizes patient-derived induced pluripotent
stem cells (iPSCs) from dilated cardiomyopathy (DCM) patients (Sun et al., 2012) and matched
non-DCM relatives to study cellular mechanisms of DCM pathogenesis. They find that iPSC
cardiomyocytes have proper β-adrenergic signaling while iPSCs from DCM patients exhibit
impaired response to β-adrenergic agonist isoproterenol (ISO), which, physiologically, would be
expected to compound the mechanical deficit associated with a mutation in troponin T (TnT).
Surprisingly, Wu et al. (2015) find that the mechanisms of altered β-adrenergic signaling involve
a direct role for TnT in epigenetic control of phosphodiesterase (PDE) expression, and that the
mutation affects TnT function not only in the myofilament lattice, but also in the nucleus. This
foundational work demonstrates the utility of iPSC-CMs for direct comparison of healthy vs.
diseased tissues by providing a platform for identifying previously unrecognized molecular and
cellular mechanisms in the progression of DCM.
The mutation studied by Wu et al. (2015) is a point mutation in the gene for the cardiac
isoform of TnT, resulting in a single amino acid change (TNNT2 R173W) in or adjacent
to TnT’s tropomyosin-binding region. Many DCM mutations in myofilament proteins affect
muscle function by decreasing Ca2+-sensitivity (e.g., when assaying Ca2+-dependent myofibrillar
MgATPase activity, sliding speed of reconstituted thin filaments in motility assays, or force
generation by permeabilized muscle preparations; Willott et al., 2010; Watkins et al., 2011); in
other words, more cytoplasmic Ca2+ would be required to achieve the same functional response.
This is indeed the case for the TNNT2 R173W mutation which shifts Ca2+sensitivity of myosin
S1 MgATPase activity rightward (toward higher [Ca2+]) by almost 0.1 pCa units, with little or
no effect on the maximum MgATPase activity or the maximum sliding speed of thin filaments
in motility assays (Sommese et al., 2013). This altered Ca2+-responsiveness of the myofilaments
almost certainly results directly in reduced mechanical function of the heart during systole, to the
detriment of the DCMpatient. Remodeling of the DCMheart, however, depends in part on changes
in gene expression. Mechanisms of altered gene regulation in cardiomyopathies have typically
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focused on changes in Ca2+-signaling, mechanosensing, and/or
energy metabolism (Frey et al., 2004; Ahmad et al., 2005; Kataoka
et al., 2007; Lakdawala et al., 2012; Moore et al., 2012; LeWinter
and Granzier, 2014). Wu et al. (2015) invoke a novel and more
direct role of TnT in gene regulation.
Wu et al. (2015) found that TnT was present in one-third of
nuclei from iPSCs derived from DCM patients with the TNNT2
R173W mutation, compared to ∼5% of nuclei of iPSCs derived
from normal individuals. TnT is an abundant myofilament
protein present in the sarcomere, responsible for attachment of
the troponin complex to tropomyosin and transmission of the
Ca2+ signal that activates systolic cardiac contraction (Figure 1).
Although TnT contains a strong nuclear localization signal
(NLS), its functional role in the nucleus of striated muscle
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FIGURE 1 | The R173W mutation is associated with increased nuclear TnT in DCM patients. Wu et al. (2015) show nuclear TnT is associated with
demethylases, and catalog an altered epigenetic landscape of phosphodiesterase (PDE) genes in DCM iPSCs (purple lollipops represent H3K4me3 and green
lollipops represent H3K27me3), which may lead to increased transcription of PDE genes in DCM patients.
myocytes is poorly understood (Bergmann et al., 2009; Zhang
et al., 2015, 2016). Identification of TnT interacting proteins in
the nucleus is critical to understanding its function.
Wu et al. (2015) performed co-immunoprecipitation studies
in cardiomyocyte nuclear extracts to identify TnT interacting
proteins. They found that TnT is associated with histone
demethylases KDM1A and KDM5A, as well as histone H3.
Furthermore, they characterized chromatin patterns of the
PDE 2A and 3A genes, where the authors found significant
increases of activation marks (H3K4me3) and decreased
repressive marks (H3K27me3) in sequences defined by the
authors as regions 1 and 2. Assuming high specificity for the
various antibodies used throughout their assays, these results
suggest that TnT normally plays a role in the epigenetic
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regulation of at least these PDE genes. Their study furthermore
demonstrates that a TnT mutation not only affects sarcomeric
function, but also contributes to the improper regulation of
both nuclear localization of TnT and PDE gene expression
in DCM patients (Figure 1). Precise epigenetic regulation
of cardiomyocyte differentiation as well as regulation of
expression in a cell-type-specific manner has been recently
documented, demonstrating this layer of information is critical
for understanding cardiomyocyte (dys)function (Paige et al.,
2012; Wamstad et al., 2012; O’Meara and Lee, 2015; Preissl et al.,
2015). An improper epigenetic landscape likely contributes to
inappropriate regulation of many genes, and it will be important
for future work to explore other known DCM mutations in the
context of genome architecture.
Wu et al. (2015) demonstrate the use of iPSCs to study a
prevalent heart disease and determine a novel role of epigenetic
regulation in pathogenesis of DCM. This finding demonstrates
that mutations in mechanical proteins that lead to DCM
pathogenesis via sarcomere dysfunction can also be exacerbated
by regulation of epigenomic state. Nuclear localization of cardiac
troponin I (TnI), cardiac troponin C (TnC), and cardiac TnT has
been shown in rat neonatal ventricular cardiomyocytes, but their
relationship with one another, and presumably tropomyosin and
actin, in the nucleus has yet to be clearly established (Asumda and
Chase, 2012). Interestingly, co-IP data from Wu et al. (2015) did
not identify TnI or tropomyosin as interacting partners of nuclear
TnT. It may be the case that these partners in thin filament
regulation have independent roles in the nucleus. Because these
proteins are often mutated in DCM patients, further studies are
necessary to not only delineate the function of these proteins
in the nucleus in normal individuals, but to determine whether
the unique mechanisms identified by Wu et al. (2015) (i.e.,
unexpected changes in nuclear localization and unexpected
interactions with other molecules, which in this instance affect
epigenetic regulation of physiologically important genes) are
specific only to the R173W mutation in TNNT2, or if they
are more commonly associated with other myofilament protein
mutations and other mutations that cause cardiomyopathies
(Schoffstall et al., 2011; Chase et al., 2013; Hershberger et al.,
2013; Teekakirikul et al., 2013; Brunet et al., 2014; Ho et al., 2015;
Teo et al., 2015). The involvement of nuclear mechanical proteins
in regulation of chromatin, and thus expression, is a new and
important aspect of DCM pathogenesis.
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